US Stock MarketDetailed Quotes

STRO Sutro Biopharma

Watchlist
  • 2.650
  • -0.040-1.49%
Close Nov 29 13:00 ET
  • 2.790
  • +0.140+5.28%
Post 17:01 ET
218.52MMarket Cap-1709P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Trytosaveabit
    Trytosaveabit
    Nov 1 07:03
    Update
    $Sutro Biopharma (STRO.US)$ Reuters· 2 mins ago
    Sutro Biopharma Announces Initiation of the Registration-Enabling RefrΑMe-P1 Trial With Luvelta for Pediatric Patients With Cbf/Glis Aml
    Jaguar8
    Jaguar8
    Nov 1 07:02
    NEWS
    $Sutro Biopharma (STRO.US)$
    Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
    Sutro Biopharma has initiated REFRαME-P1, a registration-enabling trial of luveltamab tazevibulin (luvelta) for pediatric patients with CBF/GLIS AML. The study follows encouraging compassionate use data presented in December 2023, showing 42% complete remission in patients with ≥5% blasts. CBF/GLIS AML is a rare, aggressive leuke...
    Jaguar8
    Jaguar8
    Oct 10 15:06
    NEWS
    $Sutro Biopharma (STRO.US)$
    Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
    Sutro Biopharma (NASDAQ: STRO) is hosting an investor webcast to showcase its proprietary cell-free platform and next-generation ADC innovation. The company highlights three approaches: increasing potency safely with higher drug-antibody ratio exatecan ADCs, combining payloads to overcome tumor resistance with dual-payload ADCs (ADC2), and delivering immunostimulatory...
    Jaguar8
    Jaguar8
    Sep 14 02:03
    WEEKEND NEWS
    $Sutro Biopharma (STRO.US)$
    Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
    Sutro Biopharma (NASDAQ: STRO) announced updated data from its Phase 1b study of luveltamab tazevibulin (luvelta) in combination with bevacizumab for epithelial ovarian cancer (EOC) at ESMO 2024. Key findings include:
    - 56% objective response rate at the recommended phase 2 dose (RP2D) of 4.3 mg/kg luvelta with 15 mg/kg bevacizumab
    - 35% overal...
    Jaguar8
    Jaguar8
    Aug 22 07:03
    NEWS
    $Sutro Biopharma (STRO.US)$
    Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer
    Sutro Biopharma (NASDAQ: STRO) has initiated the REFRαME-L1 global Phase 2 study of luveltamab tazevibulin (luvelta) for non-small cell lung cancer (NSCLC)patients with Folate Receptor-α (FRα) expressing tumors.
    The trial is now open for enrollment, with initial data expected in H1 2025. Luvelta, an antibody drug conjugate (ADC), shows promise...
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data